1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Original Article
You have full text access to this OnlineOpen article
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis
Article first published online: 7 MAR 2002
DOI: 10.1002/art.10139
Copyright © 2002 by the American College of Rheumatology
1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Additional Information
How to Cite
Maksymowych, W. P., Jhangri, G. S., Fitzgerald, A. A., LeClercq, S., Chiu, P., Yan, A., Skeith, K. J., Aaron, S. L., Homik, J., Davis, P., Sholter, D. and Russell, A. S. (2002), A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis. Arthritis & Rheumatism, 46: 766–773. doi: 10.1002/art.10139
Publication History
- Issue published online: 7 MAR 2002
- Article first published online: 7 MAR 2002
- Manuscript Accepted: 24 OCT 2001
- Manuscript Received: 27 JUL 2001
Funded by
- Arthritis Society of Canada
- Canadian Institutes of Health. Grant Number: MCT-37411
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1
- 2, , , Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis, The American Journal of the Medical Sciences, 2012, 343, 5, 357
- 3, , Hypertrophic Osteoarthropathy in Eisenmenger Syndrome, Congenital Heart Disease, 2012, 7, 3Direct Link:
- 4, , , , Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition, Current Opinion in Rheumatology, 2012, 24, 3, 252
- 5, , , , Assessment of the efficacy of pulse Ibandronate therapy in non-steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study, Indian Journal of Rheumatology, 2011, 6, 2, 55
- 6, , , , , , , Comment définir l’activité d’une spondylarthrite ?, Revue du Rhumatisme, 2011, 78, S215
- 7, , , , , La “poussée†dolorosa acuta dell’artrosi di ginocchio con concomitante edema midollare: efficacia del trattamento con bisfosfonati parenterali, Archivio di Ortopedia e Reumatologia, 2011, 121, 2-3, 41
- 8
- 9
- 10, Spondyloarthropathies: Management of AS—new guidelines in the spotlight, Nature Reviews Rheumatology, 2011, 7, 9, 504
- 11, , , , , , , , The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis, Joint Bone Spine, 2011, 78, 2, 188
- 12
- 13
- 14, , , , Advantages in early recognition and treatment of psoriatic arthritis, International Journal of Clinical Rheumatology, 2010, 5, 4, 461
- 15, , , , , , , , , Indian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies, Indian Journal of Rheumatology, 2010, 5, 1, 16
- 16
- 17, , , Pulse Pamidronate therapy in NSAID refractory ankylosing spondylitis. Is it effective?–An open label study, Indian Journal of Rheumatology, 2010, 5, 4, 171
- 18, , , , , , The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis, Clinical Rheumatology, 2010, 29, 7, 793
- 19, Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists, Best Practice & Research Clinical Rheumatology, 2010, 24, 5, 683
- 20, , , Utilidad de los fármacos modificadores de enfermedad (FAME) en el tratamiento de las espondiloartropatÃas, Seminarios de la Fundación Española de ReumatologÃa, 2010, 11, 3, 107
- 21
- 22, , A systematic medline analysis of therapeutic approaches in ankylosing spondylitis, Rheumatology International, 2009, 29, 10, 1123
- 23, , Ankylosing spondylitis: recent developments and anaesthetic implications, Anaesthesia, 2009, 64, 5Direct Link:
- 24, Assessment and treatment of psoriatic spondylitis, Current Rheumatology Reports, 2009, 11, 4, 278
- 25, , , , Association between the use of serotonin receptor 2A–blocking antidepressants and joint disorders, Arthritis Care & Research, 2009, 61, 10Direct Link:
- 26, , , , , , , Pamidronate treatment in rheumatology practice: a comprehensive review, Clinical Rheumatology, 2009, 28, 12, 1359
- 27
- 28, Do bisphosphonates and statins have a role in spondyloarthritis management?, Current Rheumatology Reports, 2008, 10, 5, 364
- 29, , , , , , , , Evidence-based recommendations for the monitoring and treatment of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology, International Journal of Rheumatic Diseases, 2008, 11, 1Direct Link:
- 30, , , , , , , Ilium Osteitis as the Main Manifestation of the SAPHO Syndrome: Response to Infliximab Therapy and Review of the Literature, Seminars in Arthritis and Rheumatism, 2008, 37, 5, 299
- 31, , Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic, Seminars in Arthritis and Rheumatism, 2008, 38, 2, 83
- 32
- 33, , , Molecular mechanisms of inflammatory bone damage: emerging targets for therapy, Trends in Molecular Medicine, 2008, 14, 6, 245
- You have free access to this content34, , Osteoporosis in ankylosing spondylitis, International Journal of Rheumatic Diseases, 2008, 11, 4Direct Link:
- 35, , , , , , , Presence of spondyloarthropathy and its clinical profile in patients with hypoparathyroidism, Clinical Endocrinology, 2008, 68, 2Direct Link:
- 36, , Tumour necrosis factor inhibitors in ankylosing spondylitis, Internal Medicine Journal, 2008, 38, 10Direct Link:
- 37
- 38, , Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis, Current Opinion in Rheumatology, 2007, 19, 4, 340
- 39, , Appropriate management of axial spondyloarthritis, Current Rheumatology Reports, 2007, 9, 5, 375
- 40, , , , , , , , , , , , , , , Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 2007, 74, 4, 330
- 41
- 42
- 43, , , , , , , , Extraintestinal Manifestations of Crohn’s Disease, Digestion, 2007, 76, 2, 141
- 44, , , , , , , , , , , , , , , Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 2007, 74, 4, 346
- 45, , Recent Developments in Bisphosphonate Therapy, Seminars in Arthritis and Rheumatism, 2007, 37, 1, 1
- 46, , , Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy, Best Practice & Research Clinical Rheumatology, 2006, 20, 3, 539
- 47, , Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis, Expert Opinion on Pharmacotherapy, 2006, 7, 7, 869
- 48, , Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis, Nature Clinical Practice Rheumatology, 2006, 2, 4, 211
- 49, , , , , , , , Empfehlungen für das Management der ankylosierenden Spondylitis gemäß ASAS/EULAR, Zeitschrift für Rheumatologie, 2006, 65, 8, 728
- 50, , , , , , , , Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone–cartilage interface and subchondral bone marrow, Arthritis & Rheumatism, 2006, 54, 6Direct Link:
- 51, Infliximab: a chimeric anti-TNF- monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides, Therapy, 2006, 3, 2, 191
- 52, Infliximab: a chimeric anti-TNF-α monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides, Therapy, 2006, 3, 2, 191
- 53, , , , , Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study, Osteoporosis International, 2006, 17, 11, 1659
- 54, , , Pharmacological management of SAPHO syndrome, Expert Opinion on Investigational Drugs, 2006, 15, 10, 1229
- 55, , , , , Pharmacological management of undifferentiated spondyloarthropathies, Expert Opinion on Investigational Drugs, 2006, 15, 1, 39
- 56, , , Spondylarthrite ankylosante et ostéoporose, La Revue de Médecine Interne, 2006, 27, 5, 392
- 57, , , , The treatment of the rheumatological manifestations of the inflammatory bowel diseases, Rheumatology International, 2006, 26, 11, 953
- 58
- 59, Use NSAIDs to relieve pain and stiffness in patients with ankylosing spondylitis and reserve tumour necrosis factor-?? antagonists for NSAID-refractory patients, Drugs & Therapy Perspectives, 2006, 22, 5, 11
- 60, , Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies, Expert Opinion on Pharmacotherapy, 2005, 6, 1, 35
- 61, , , , , , Densité minérale et métabolisme osseux des spondylarthropathies, La Revue de Médecine Interne, 2005, 26, 5, 381
- 62, , , , , , , , Extraintestinal Manifestations of Crohn’s Disease, Digestion, 2005, 71, 1, 31
- 63, , Infliximab for the treatment of ankylosing spondylitis, Expert Opinion on Biological Therapy, 2005, 5, 8, 1095
- 64, , Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies, Drugs & Aging, 2005, 22, 6, 451
- 65, , Management and treatment of ankylosing spondylitis, Current Opinion in Rheumatology, 2005, 17, 4, 418
- 66, Primer documento de consenso de la Sociedad Española de ReumatologÃa sobre el uso de antagonistas del TNF-α en las espondiloartritis, ReumatologÃa ClÃnica, 2005, 1, 1, 32
- 67, , The management of secondary osteoporosis, Best Practice & Research Clinical Rheumatology, 2005, 19, 6, 1021
- 68, Tratamiento del sÃndrome SAPHO, Seminarios de la Fundación Española de ReumatologÃa, 2005, 6, 1, 11
- 69, Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis, Seminars in Arthritis and Rheumatism, 2005, 34, 4, 668
- 70, , , , , A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity, Rheumatology International, 2004, 25, 4, 280
- 71
- 72, , Anti-TNF-α therapy in ankylosing spondylitis, Expert Opinion on Pharmacotherapy, 2004, 5, 7, 1497
- 73, , , , , , , Anti–tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis, Arthritis Care & Research, 2004, 51, 2Direct Link:
- 74, , Bisphosphonates: Environmental protection for the joint?, Arthritis & Rheumatism, 2004, 50, 7Direct Link:
- 75, Major advances in ankylosing spondylitis: more to come, Drug Discovery Today: Therapeutic Strategies, 2004, 1, 3, 383
- 76
- 77
- 78, , , Recent advances in the treatment of the spondyloarthropathies, Current Opinion in Rheumatology, 2004, 16, 4, 357
- 79, , , , Results from an open-label extension study of etanercept in ankylosing spondylitis, Arthritis Care & Research, 2004, 51, 2Direct Link:
- 80, , , , , Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity, Arthritis & Rheumatism, 2004, 50, 11Direct Link:
- 81, Update in spondylarthropathy, Arthritis Care & Research, 2004, 51, 1Direct Link:
- 82, , , , A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis: Comment on the article by Maksymowych et al, Arthritis & Rheumatism, 2003, 48, 2Direct Link:
- 83, , , , , Biologic therapies in the spondyloarthritis: new opportunities, new challenges, Current Opinion in Rheumatology, 2003, 15, 4, 394
- 84, Bisphosphonates: new indications and methods of administration, Current Opinion in Rheumatology, 2003, 15, 4, 458
- 85, Diagnosis and treatment of enthesitis, Rheumatic Disease Clinics of North America, 2003, 29, 3, 549
- 86, Disease-modifying antirheumatic drug therapy for spondyloarthropathies, Current Opinion in Rheumatology, 2003, 15, 3, 205
- 87, , , Drug-induced and toxic myopathies, Best Practice & Research Clinical Rheumatology, 2003, 17, 6, 877
- 88, , , New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate, Rheumatic Disease Clinics of North America, 2003, 29, 3, 481
- 89, Recent Advances in the Treatment of Spondyloarthropathy, Journal of the Korean Medical Association, 2003, 46, 11, 972
- 90, , Treatment of extraintestinal manifestations in inflammatory bowel disease, Current Treatment Options in Gastroenterology, 2003, 6, 3, 201
- 91, , Anti-TNF agents for the treatment of spondyloarthropathies, Expert Opinion on Emerging Drugs, 2002, 7, 2, 235
- 92, , Juvenile spondyloarthropathies and related arthritis, Current Opinion in Rheumatology, 2002, 14, 5, 531
- 93, Novel therapies in the treatment of spondyloarthritis, Expert Opinion on Investigational Drugs, 2002, 11, 7, 937
- 94, , , Therapy for ankylosing spondylitis: new treatment modalities, Best Practice & Research Clinical Rheumatology, 2002, 16, 4, 631